Know Cancer

or
forgot password

Utility of Whole-Body 18-Fluorodeoxyglucose Positron Emission Tomography (PET) In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases


N/A
18 Years
N/A
Not Enrolling
Both
Colorectal Carcinoma

Thank you

Trial Information

Utility of Whole-Body 18-Fluorodeoxyglucose Positron Emission Tomography (PET) In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases


Inclusion Criteria:



- initial diagnosis of colorectal carcinoma confirmed by the Pathology Department of
Memorial Hospital or by diagnostic barium enema if the primary tumor is still in
place.

- a candidate for liver resection for metastatic colorectal cancer as defined by
members of the Department of Surgery of Memorial Hospital. Patients with metastatic
colorectal cancer isolated to the colon, rectum, or liver are eligible. In addition,
patients with limited, resectable pulmonary metastases are eligible.

Exclusion Criteria:

- Patients must not be pregnant; females of child bearing age must use an adequate form
of contraception.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

To assess if whole body 18F-FDG-PET enhances our ability to detect metastatic colorectal cancer restricted to liver and lung over conventional imaging such as CT and to determine the accuracy of PET in imaging extrahepatic tumors.

Outcome Time Frame:

conclusion of the study

Safety Issue:

No

Principal Investigator

Yuman Fong, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

98-015

NCT ID:

NCT00588549

Start Date:

July 1998

Completion Date:

March 2009

Related Keywords:

  • Colorectal Carcinoma
  • Carcinoma
  • Colorectal Neoplasms
  • Neoplasm Metastasis

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021